Literature DB >> 20843635

Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking.

Michelle A Tanchuck1, Naomi Yoneyama, Matthew M Ford, Andrea M Fretwell, Deborah A Finn.   

Abstract

Drinking to intoxication or binge drinking is a hallmark characteristic of alcohol abuse. Although hard to model in rodents, the scheduled high alcohol consumption (SHAC) procedure generates high, stable ethanol intake and blood ethanol concentrations in mice to levels consistent with definitions of binge drinking. The purpose of the present studies was to determine the effects of pharmacological manipulation of the opioidergic, glutamatergic, and γ-aminobutyric acid (GABA)ergic systems on binge drinking with the SHAC procedure. Parallel manipulations were conducted in mice trained in operant self-administration of either sucrose or ethanol. For the SHAC procedure, genetically heterogeneous Withdrawal Seizure Control mice were given varying periods of fluid access, with a 30-min ethanol session every third day (total of seven). Mice were pretreated intraperitoneally with naltrexone (0, 0.6, or 1.25 mg/kg), baclofen (0, 2.5, or 5.0 mg/kg), or 2-methyl-6-(phenylethynyl)-pyridine (MPEP; 0, 3.0, or 10.0 mg/kg) before each ethanol session. For the operant self-administration procedure, separate groups of C57BL/6 mice were trained to complete a single response requirement (16 presses on the active lever) to gain 30 min of access to an ethanol or a sucrose solution. Mice received pretreatments of the same doses of naltrexone, MPEP, or baclofen before the self-administration sessions, with saline injections on intervening days. Naltrexone produced a dose-dependent decrease in binge drinking, and the highest dose also significantly decreased operant self-administration of ethanol and sucrose. Both doses of baclofen significantly decreased binge alcohol consumption, but the higher dose also tended to decrease water intake. The highest dose of baclofen also significantly decreased operant self-administration of sucrose. MPEP (10 mg/kg) significantly decreased binge alcohol consumption and sucrose self-administration. These results indicate that manipulation of the opioidergic, glutamatergic, and GABAergic systems significantly decreased binge drinking.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843635      PMCID: PMC3003942          DOI: 10.1016/j.alcohol.2010.07.009

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  88 in total

Review 1.  A new assessment of the ability of oral ethanol to function as a reinforcing stimulus.

Authors:  H H Samson; C L Czachowski; C J Slawecki
Journal:  Alcohol Clin Exp Res       Date:  2000-06       Impact factor: 3.455

2.  Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.

Authors:  G Colombo; R Agabio; M A Carai; C Lobina; M Pani; R Reali; G Addolorato; G L Gessa
Journal:  Alcohol Clin Exp Res       Date:  2000-01       Impact factor: 3.455

3.  Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.

Authors:  G Addolorato; F Caputo; E Capristo; G Colombo; G L Gessa; G Gasbarrini
Journal:  Alcohol Clin Exp Res       Date:  2000-01       Impact factor: 3.455

4.  A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats.

Authors:  Michael F Stromberg; Margaret R Rukstalis; Scott A Mackler; Joseph R Volpicelli; Charles P O'Brien
Journal:  Pharmacol Biochem Behav       Date:  2002-05       Impact factor: 3.533

5.  Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.

Authors:  M E McCaul; G S Wand; T Eissenberg; C A Rohde; L J Cheskin
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

6.  Ethanol reinforcement in nondeprived mice: effects of abstinence and naltrexone.

Authors:  L D Middaugh; A M Lee; A L Bandy
Journal:  Alcohol Clin Exp Res       Date:  2000-08       Impact factor: 3.455

7.  Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.

Authors:  M F Stromberg; S A Mackler; J R Volpicelli; C P O'Brien
Journal:  Alcohol       Date:  2001-02       Impact factor: 2.405

8.  Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives.

Authors:  Giovanni Addolorato; Lorenzo Leggio; Silvia Cardone; Anna Ferrulli; Giovanni Gasbarrini
Journal:  Alcohol       Date:  2009-11       Impact factor: 2.405

Review 9.  Role of the GABA(B) receptor in alcohol-seeking and drinking behavior.

Authors:  Paola Maccioni; Giancarlo Colombo
Journal:  Alcohol       Date:  2009-11       Impact factor: 2.405

10.  The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats.

Authors:  Giancarlo Colombo; Salvatore Serra; Giuliana Brunetti; Giuliana Atzori; Marialaura Pani; Giovanni Vacca; Giovanni Addolorato; Wolfgang Froestl; Mauro A M Carai; Gian Luigi Gessa
Journal:  Alcohol Alcohol       Date:  2002 Sep-Oct       Impact factor: 2.826

View more
  26 in total

Review 1.  The neurobiology of binge-like ethanol drinking: evidence from rodent models.

Authors:  Gretchen M Sprow; Todd E Thiele
Journal:  Physiol Behav       Date:  2012-01-08

Review 2.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 3.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

4.  High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.

Authors:  John C Crabbe; Angela R Ozburn; Pamela Metten; Amanda Barkley-Levenson; Jason P Schlumbohm; Stephanie E Spence; Wyatt R Hack; Lawrence C Huang
Journal:  Pharmacol Biochem Behav       Date:  2017-08-05       Impact factor: 3.533

5.  Inhibition of Glyoxalase 1 reduces alcohol self-administration in dependent and nondependent rats.

Authors:  Giordano de Guglielmo; Dana E Conlisk; Amanda M Barkley-Levenson; Abraham A Palmer; Olivier George
Journal:  Pharmacol Biochem Behav       Date:  2018-03-02       Impact factor: 3.533

6.  Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons.

Authors:  Angela N Duke; Barbara J Kaminski; Elise M Weerts
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

Review 7.  Rodent models and mechanisms of voluntary binge-like ethanol consumption: Examples, opportunities, and strategies for preclinical research.

Authors:  Brandon M Fritz; Stephen L Boehm
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-06-02       Impact factor: 5.067

8.  Ivermectin reduces alcohol intake and preference in mice.

Authors:  Megan M Yardley; Letisha Wyatt; Sheraz Khoja; Liana Asatryan; Marcia J Ramaker; Deborah A Finn; Ronald L Alkana; Nhat Huynh; Stan G Louie; Nicos A Petasis; Marco Bortolato; Daryl L Davies
Journal:  Neuropharmacology       Date:  2012-03-23       Impact factor: 5.250

9.  GABAB receptor activation attenuates the stimulant but not mesolimbic dopamine response to ethanol in FAST mice.

Authors:  Sarah E Holstein; Na Li; Amy J Eshleman; Tamara J Phillips
Journal:  Behav Brain Res       Date:  2012-09-13       Impact factor: 3.332

10.  Effects of vigabatrin, an irreversible GABA transaminase inhibitor, on ethanol reinforcement and ethanol discriminative stimuli in mice.

Authors:  William C Griffin; Shaun A Nguyen; Christopher P Deleon; Lawrence D Middaugh
Journal:  Behav Pharmacol       Date:  2012-04       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.